STN: BL 103475
Proper Name: Hepatitis A Vaccine
Tradename: HAVRIX
Manufacturer: GlaxoSmithKline Biologicals
Indication:

• HAVRIX is indicated for active immunization against disease caused by hepatitis A virus (HAV).
• HAVRIX is approved for use in persons 12 months of age and older. Primary immunization should be administered at least 2 weeks prior to expected exposure to HAV.

Product Information

• Package Insert - HAVRIX

Supporting Documents

• October 27, 2023 Approval Letter - HAVRIX
• December 3, 2021 Approval Letter - HAVRIX
• December 19, 2018 Approval Letter - HAVRIX
• Supporting Documents older than three years - HAVRIX